Another group utilized a similar platform, but functionalized the EVs to target EpCAM-positive HCC cells.82 These studies along with others previously mentioned61, 62, 82 provide direct evidence that therapeutically targeting oncogenic mutations with siRNAs are effective approaches to treat HCC. The gene discussed is EPCAM; the disease is hepatocellular carcinoma.